在心力衰竭高血压患者的多种人群中控制血压
Hieu Minh Nguyen1, Rohan Mahabaleshwarkar1, Shuktika Nandkeolyar2
1Center for Health System Sciences (CHASSIS), Atrium Health, Charlotte, North Carolina.
The American journal of cardiology
|October 8, 2023
概括
许多心力衰竭 (HF) 的高血压患者无法达到血压 (BP) 的目标. 种族,性别和保险状况等因素会影响血压控制,强调需要改进治疗策略和健康公平.
科学领域:
- 心脏病学 心脏病学
- 高血压管理 高血压管理
- 健康 公平 卫生 公平
背景情况:
- 患有心力衰竭 (HF) 的高血压患者是高风险组.
- 目前的指导方针建议静脉血压 (BP) <130 mm Hg对于HF患者.
- 在这个易受伤害的人群中,血压控制及其相关物质尚未得到充分理解.
研究的目的:
- 为了确定高血压患者的高血压控制水平.
- 为了确定与这个队列中低于最佳的血压控制相关的因素.
- 为改善治疗和健康公平的战略提供信息.
主要方法:
- 在2019年对10,802名患有高血压的高血压患者进行了回顾性分析.
- 在夏洛特大都会地区利用了一个大型的卫生系统.
- 采用多变量逻辑回归来确定高血压的相关物质.
主要成果:
- 近一半 (48.1%) 的缩血压≥130 mm Hg;57.6%的血压≥130/80 mm Hg.
- 静脉血压升高与种族-种族,性别,保险状况和初级保健医生 (PCP) 归因有关.
- 非西班牙裔黑人,女性和没有保险的患者患高血压的几率较高;PCP归因与更低的几率有关.
结论:
- 低于最佳的血压控制在患有高血压的高血压患者中普遍存在.
- 种族,性别,保险和PCP接入是影响BP控制的重要因素.
- 有针对性的干预措施是必要的,以优化治疗和推进这一群体的健康公平.
相关概念视频
01:30Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:30Blood Pressure
1.2K
Blood pressure (BP) is the pressure or force of blood exerted on the artery's walls as it circulates through the body. It is essential for maintaining blood flow throughout the body.
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
1.2K
01:22Heart Failure Drugs: β-Blockers
349
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
349
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445